Immunogenetics of autoimmune liver disease: Risk factors for susceptibility and progression

Liver Immunology: Principles and Practice

Volumn , Issue , 2007, Pages 221-233

  Donaldson, Peter Tickell ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78049468871     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-59745-518-3_18     Document Type: Chapter

References (104)

1. Haines JL, Pericak-Vance MA. Overview of mapping common and genetically complex disease genes. In: Haines JL, Pericak- Vance MA, eds. Approaches to Gene Mapping in Complex Diseases. New York, USA: John Wiley & Sons, 1998: 1-16
2. NCBI Single Nucleotide Polymorphism. http://www.ncbi.nlm. nih.gov/SNP/. Last accessed May 21, 2007
3. Carlson CS, Eberle MA, Kruglyak L, Nickerson DA. Mapping complex disease loci in whole genome association studies. Nature 2004; 429:446-452
4. Hirschhorn JN, Lohmueller K, Bryne E, Hirschhorn K. A comprehensive review of genetic association studies. Genet Med 2002; 2: 45-61
5. Donaldson PT. Recent advances in clinical practice: Genetics of liver disease: Immunogenetics and disease pathogenesis. Gut 2004; 53:599-608
6. Colhoun H, McKeigue PM, Smith GD. Problems of reporting genetic associations with complex outcomes. Lancet 2003; 361: 865-872
7. Donaldson PT. Genetics of autoimmune and viral liver disease; understanding the issues. Hepatol 2004; 41:327-332
8. Bentley DR. Genomes for medicine. Nature 2004; 429:440-445
9. Donaldson P, Agarwal K, Craggs A, Craig W, James O, Jones D. HLA and interleukin-1 gene polymorphisms in primary biliary cirrhosis associations with disease progression and disease susceptibility. Gut 2001; 48:397-402
10. Russo E. The new approach to autoimmune disease. Scientist 2003; May:30-31
11. McGovern DPB, Hysi P, Ahmad T, et al, Association between a complex insertion/deletion polymorphism in NOD1 (CARD4) and susceptibility to inflammatory bowel disease. Hum Mol Genet 2005; 14:1245-1250
12. Horton R, Wilming L, Rand V, et al. Gene map of the extended human MHC. Nat Rev Genet 2004; 5:889-899
13. The Anthony Nolan Trust. www.anthonynolan.com/HIH/nomenclature. Last accessed May 21, 2007
14. Bauer S, Groh V, Wu J, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress inducible MICA. Science 1999; 285: 727-729
15. Norris S, Doherty DG, McEntee G, Traynor O, Hegarty JE, O'Farrelly C. Natural T cells in the human liver: Cytotoxic lymphocytes with dual T cell and natural killer cell phenotype and function are phenotypically heterogeneous and include Va24JaQ and γσ; T cell receptor bearing cells. Hum Immunol 1999; 60: 20-31
16. Mackay IR, Morris PJ. Association of autoimmune active hepatitis with HL-A1, 8. Lancet 1972; ii:793-795
17. Oplez G, Votgen AGM, Summerskill WHJ, Schalm SW, Terasaki PI. HLA determinant in chronic active liver disease: A possible relation of HLA-Dw3 to prognosis. Tissue Antigens 1977; 9:36-40
18. Donaldson PT, Doherty DG, Hayllar KM, McFarlane IG, Johnson PJ, Williams R. Susceptibility to autoimmune chronic active hepatitis: Human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology 1991; 13:701-706
19. Doherty DG, Donaldson PT, Underhill JA, et al. Allelic sequence variation in the HLA class II genes and proteins in patients with autoimmune hepatitis. Hepatology 1994; 19:609-615
20. Strettell MDJ, Donaldson PT, Thompson LJ, et al. Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis. Gastroenterology 1997; 112:2028-2035
21. Strettell MDJ, Thomson LJ, Donaldson PT, Bunce M, O'Niell CM, Williams R. HLA-C genes and susceptibility to type I autoimmune hepatitis. Hepatology 1997; 26:1203-1206
22. Cookson S, Constantini PK, Clare M, et al. Frequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis. Hepatology 1999; 30:851-856
23. Bittencourt LP, Palacios SA, Cancado ELR, et al. Autoimmune hepatitis in Brazilian patients is not linked to tumour necrosis factor a polymorphisms at position -308. Hepato 2001; 35:24-28
24. Manabe K, Donaldson PT, Underhill JA, et al. HLA A1-B8-DR3- DQ2-DPB1. 0401 extended haplotype in autoimmune hepatitis. Hepatology 1993; 18:1334-1337
25. Seki T, Ota M, Furuta S, et al. HLA class II molecules and autoimmune hepatitis susceptibility in Japanese patients. Gastroenterology 1992; 103:1041-1047
26. Ota M, Seki T, Kiyosawa K, et al. A possible association between basic amino acids at position 13 of DRB1 chains and autoimmune hepatitis. Immunogenetics 1992; 36:49-55
27. Vazquez-Garcia MN, Alaez C, Olivo A, et al. MHC class II sequences of susceptibility and protection in Mexicans with autoimmune hepatitis. J Hepatol 1998; 28:985-990
28. Fainboim L, Marcos Y, Pando M, et al. Chronic active autoimmune hepatitis in children: Strong association with a particular HLA-DR6 (DRB1.*1301) haplotype. Hum Immunol 1994; 41:146-150
29. Pando M, Lariba J, Fernadez GC, et al. Paediatric and adult forms of type 1 autoimmune hepatitis in Argentina: Evidence for differential genetic predisposition. Hepatology 1999; 30:1374-1380
30. Djilali-Saiah I, Renous R, Caillat-Zucman S, Debray D, Alvarez F. Linkage disequlibrium between HLA class II region and autoimmune heptatitis in pediatric patients. J Hepatol 2004; 40: 904-909
31. Sanchez-Urdazpal L, Czaja AJ, van Hoek B, et al. Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. Hepatology 1992; 15: 215-221
32. Czaja AJ, Donaldson PT, Lohse AW. Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 AIH. Am J Gastroenterol 2002; 97:413-419
33. Czaja AJ, Donaldson PT. Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis. Immunol Rev 2000; 174:250-259
34. Donaldson PT, Norris S. Immunogenetics in PSC. Ballieres Best Pract Res in Clin Gastroenterol 2001; 15:611-627
35. Donaldson PT, Farrant JM, Wilkinson ML, Hayllar K, Portmann BC, Williams R. Dual association of HLA DR2 and DR3 with primary sclerosing cholangitis. Hepatology 1991; 13:129-133
36. Farrant JM, Doherty DG, Donaldson PT, et al. Amino acid substitutions at position 38 of the DRβ polypeptide confers susceptibility and protection from primary sclerosing cholangitis. Hepatology 1992; 16:390-395
37. Mehal WZ, Lo Y-MD, Wordsworth BP, et al. HLA DR4 is a marker for rapid disease progression in primary sclerosing cholangitis. Gastroenterology 1994; 106:160-167
38. Underhill JA, Donaldson PT, Manabe K, Doherty DG, Williams R. HLA DPB polymorphism in primary sclerosing cholangitis and primary biliary cirrhosis. Hepatology 1995; 21:959-962
39. Olerup O, Olsson R, Hultcrantz R, Broome U. HLA-DR and HLADQ are not markers for rapid disease progression in primary sclerosing cholangitis. Gastroenterology 1995; 108: 870-878
40. Spurkland A, Saarinen S, Boberg KM, et al. HLA class II haplotypes in primary sclerosing cholangitis patients from five European populations. Tissue Antigens 1999; 53:459-469
41. Farkkila M, Koskimies S, Karvonen A-L, Pikkarainen P, Nurmi H, Nuutinen H. HLA associations in primary sclerosing cholangitis (PSC): DR4 has a protective role? [Abstract] Gastroenterology 1999; 116: A1209. (Abstract L0127).
42. Norris S, Kondeatis E, Collins R, et al. Mapping MHC-encoded susceptibility and resistance in primary sclerosing cholangitis: The role of MICA polymorphism. Gastroenterology 2001; 120:1475-1482
43. Wiencke K, Spurkland A, Schrumpf E, Boberg KM. Primary sclerosing cholangitis is associated to an extended B8-DR3 haplotype including particular MICA and MICB alleles. Hepatology 2001; 34:625-630
44. Donaldson PT, Norris S. Evaluation of the role of MHC class II alleles, haplotypes and selected amino acid sequences in primary sclerosing cholangitis. Autoimmunity 2002; 35:555-564
45. Moloney MM, Thomson LJ, Strettell MJ, Williams R, Donaldson PT. HLA-C genes and susceptibility to primary sclerosing cholangitis. Hepatology 1998; 28:660-662
46. Bernal W, Moloney M, Underhill J, Donaldson PT. Association of tumour necrosis factor polymorphism with primary sclerosing cholangitis. J Hepatol 1999; 30:237-241
47. Gow PJ, Flemming KA, Chapman RW. Primary sclerosing cholangitis associated with rheumatoid arthritis and DR4: Is the association a marker of patients with progressive liver disease. J Hepatol 2000; 34:631-635
48. Boberg KM, Spurkland A, Rocca G, et al. The HLA-DR3, DQ2 heterozygous genotype is associated with an accelerated progression in primary sclerosing cholangitis. Scand J Gastroenterol 2001; 36: 886-890
49. Jones DEJ, Donaldson PT. Genetic factors in the pathogenesis of primary biliary cirrhosis. Clin Liver Dis 2003; 7:841-864
50. Gores GJ, Moore SB, Fisher LD, Powell FC, Dickson ER. Primary biliary cirrhosis: Association with class II major histocompatibility complex antigens. Hepatology 1987; 7:889-892
51. Underhill JA, Donaldson PT, Bray G, Doherty DG, Portmann BC, Williams R. Susceptibility to primary biliary cirrhosis is associated with the HLA DR8-DQB1.0402 haplotype. Hepatology 1992; 16: 1404-1408
52. Gregory W, Mehal W, Dunn AN, et al. Primary biliary cirrhosis: Contribution of HLA class II allele DR8. Q J Med 1993; 86: 393-399
53. Wassmuth R, Depner F, Danielsson A, Hultcrantz R, Loof L, Olson R, et al. HLA class II markers and clinical heterogeneity in Swedish patients with primary biliary cirrhosis. Tissue Antigens 2002; 59:381-387
54. Begovich AB, Klitz W, Moonsamy PV, Van de Water J, Peltz G, Gershwin ME. Genes within the HLA class II region confer both predisposition and resistance to primary biliary cirrhosis. Tissue Antigens 1994; 43:71-77
55. Stone J, Wade JA, Cauch-Dudek K, Ng C, Lindor KD, Heathcote EJ. Human leucocyte antigen class II associations in serum antimitochondrial antibodies (AMA)-positive and AMA-negative primary biliary cirrhosis. J Hepatol 2002; 36:8-13
56. Maeda T, Onishi S, Saibara T, Iwasaki S, Yamamoto Y. HLA DRw8 and primary biliary cirrhosis. Gastroenterology 1992; 103:1118
57. Seki T, Kiyosawa K, Ota M, et al. Association of primary biliary cirrhosis with human leucocyte antigen DPB1.0501 in Japanese patients. Hepatology 1993; 18:73-78
58. Oguri H, Oba S, Ogino H, et al. Susceptibility to primary biliary cirrhosis is associated with human leucocyte antigen DRB1. 0803 in Japanese patients. Int Hepatology Comm 1994; 2:263-270
59. Mukai T, Kimura A, Ishibashi H, et al. Association of HLADRB1. 0803 and . 1602 with susceptibility to primary biliary cirrhosis. Int Hepatol Comm 1995; 3:207-212
60. Invernizzi P, Battezzati PM, Crosignani A, et al. Peculiar HLA polymorphisms in Italian patients with primary biliary cirrhosis. Journal of Hepatology 2003; 38:401-406
61. Invernizzi P, Selmi C, Poli F, et al., HLA DRB1 polymorphisms in 676 Italian patients with primary biliary cirrhosis and 2028 matched healthy controls. A nation-wide population based case-control study. Hepatology 2005; 42:462A. [Abstract].
62. Donaldson PT, Baragiotta A, Henneghan MA, et al. HLA class II alleles, genotypes, haplotypes and amino acids in primary biliary cirrhosis. Hepatology 2006; 44:667-674
63. Briggs DC, Donaldson PT, Hayes P, Welsh KI, Neuberger JN, Williams R. A major histocompatibility complex Class III allotype C4B2 associated with primary biliary cirrhosis. Tissue Antigens 1987; 29:141-145
64. Manns MP, Bremm A, Schneider PM, et al. HLA DRw8 and complement C4 deficiency as risk factors in primary biliary cirrhosis. Gastroenterology 1991; 101:1367-1373
65. Donaldson PT. TNF polymorphisms in primary biliary cirrhosis: A critical appraisal. J Hepatol 1999; 31:366-368
66. Nepom GT. HLA and rheumatoid arthritis. In: Warrens A, Lechler R, eds. HLA in Health and Disease. London: Academic Press, 2000:181-186
67. Fainboim L, Velasco MCC, Marcos CY, et al. Protracted, but not acute, hepatitis A virus infection is strongly associated with HLADRB1. 1301, a marker for paediatric autoimmune hepatitis. Hepatology 2001; 33:1512-1517
68. Tapia-Conyer R, Santos JI, Cavalcanti AM, et al. Hepatitis A in Latin America: A changing epidemiologic pattern. Am J Trop Med Hyg 1999; 61:825-829
69. Groh V, Bahram S, Bauer S, Herman A, Beauchamp M, Spies T. Cell stress regulated human major histocompatibility complex class I gene-regulated in gastrointestinal epithelium. Proc Natl Acad Sci USA. 1996; 93:12445-12450
70. Martins EBG, Graham AK, Chapman RW, Fleming K. Elevation of γσ; T lymphocytes in peripheral blood and livers of patients with primary sclerosing cholangitis and other autoimmune disease. Hepatology 1996; 23:988-999
71. Fodil N, Pellet P, Laloux L, et al. MICA haplotypic diversity. Immunogenetics 1999; 49:557-560
72. Donaldson PT. Genetics in autoimmune hepatitis. Semin Liver Dis 2002; 23:353-363
73. Kristiansen OP, Larsen ZM, Pocoit F. CTLA-4 in autoimmune diseases - A general susceptibility gene to autoimmunity? Genes Immun 2000; 1:170-184
74. McCoy KD, Le Gros G. The role of CTLA-4 in the regulation of T cell immune responses. Immunol Cell Biol 1999; 77:1-10
75. Perez VL, Parijs LV, Biuckians A, Zheng XX, Strom TB, Abbas AK. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity 1997; 6:411-417
76. Ueda H, Howson JMM, Esposito L, et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003; 423:506-511
77. Agarwal K, Czaja AJ, Jones DEJ, et al. CTLA-4 polymorphisms and susceptibility to type 1 autoimmune hepatitis. Hepatoly 2000; 31:49-53
78. Agarwal K, Jones DEJ, Daly AK, et al. CTLA-4 gene polymorphism confers susceptibility to primary biliary cirrhosis. J Hepatol 2000; 32:538-541
79. Amano K, Takahashi H, Kuniyasu Y, et al. The combination of CTLA-4 and IFN-γ gene polymorphism is associated with susceptibility to PBC and influence on clinical manifestation. Hepatology 2001; 34:371A (Abstract 797).
80. Wiencke K, Boberg KM, Donaldson P, et al. No major effect of the CD28/CTLA4/ICOS gene region on susceptibility to primary sclerosing cholangitis. Scand J Gastroenterol 2006; 41:586-591
81. Simpson KJ, Lukacs NW, Colletti L, et al. Cytokines and the liver. J Hepatol 1997; 27:1120-1132
82. Mitchell SA, Grove J, Spurkland A, et al. Association of the tumour necrosis factor a-308 but not the interleukin 10-627 promoter polymorphism with genetic susceptibility to primary sclerosing cholangitis. Gut 2001; 49:288-249
83. Bittencourt PL. Palacios SA. Cancado EL. et al. Susceptibility to primary sclerosing cholangitis in Brazil is associated with HLADRB1. 13 but not with tumour necrosis factor alpha-308 promoter polymorphism. Gut 2002; 51:609-610
84. Bensen JT, Langfeld CD, Hawkins GA, et al. Nucleotide variation, haplotype structure, and association with end stage renal disease of the human interleukin-1 gene cluster. Genomics 2003; 82: 194-217
85. Donaldson PT, Norris S, Constantini PK, Harrison P, Williams R. The interleukin-1 and interleukin-10 gene polymorphisms in primary sclerosing cholangitis: No associations with disease susceptibility/ resistance. J Hepatol 2000; 32:882-886
86. Fan L-Y, Tu X-Q, Pfeiffer T, Feltens R, Stoecker W, Zhong R-Q. Genetic association of cytokine polymorphisms with autoimmune hepatitis and primary biliary cirrhosis in Chinese. World J Gastroenterol 2005; 11:2768-2772
87. Schaekal NA, McGuiness PH, Abbott CA, Gorrell MD, McCaughan GW. Identification of novel molecules and pathogenic pathways in primary biliary cirrhosis: CDNA array analysis of intrahepatic differential gene expression. Gut 2001; 49:565-576
88. Graham AM, Dollinger MM, Howie SEM, Harrison DJ. Identification of novel alleles at a polymorphic microsatellite repeat region in the human NRAMP1 gene promoter: Analysis of allele frequencies in primary biliary cirrhosis. J Med Genet 2000; 37: 150-152
89. Searle S, Blackwell JM. Evidence for a functional repeat polymorphism in the promoter of the human NRAMP1 gene that correlates with autoimmune versus infectious disease susceptibility. J Med Genet 1999; 36:295-299
90. Vilagut L, Vila J, Vinas O, et al. Cross reactivity of anti- Mycobacterium godonae antibodies with the major mitochondrial auto antigens in PBC. J Hepatol 1994; 21:673-677
91. Zappala F, Grove J, Watt FE, et al. No evidence for involvement of the interleukin-10 -592 promoter polymorphism in genetic susceptibility to primary biliary cirrhosis. J Hepatol 1998; 28:820-823
92. Bataller R, North KE, Brenner DA. Genetic polymorphisms and the progression of liver fibrosis: A critical appraisal. Hepatology 2003; 37:493-503
93. Satsangi J, Chapman RWG, Haldar N, et al. A functional polymorphism of the stromelysin gene (MMP-3) influences susceptibility to primary sclerosing cholangitis. Gastroenterology 2001; 121:124-130
94. Wiencke K, Louka AS, Spurkland A, Vatn M, Schrumpf E, Boberg KM. Association of matrix metalloproteinase-1 and -3 promoter polymorphisms with clinical subsets of Norwegian primary sclerosing cholangitis patients. J Hepatol 2004; 41:209-214
95. Pinkoski MJ, Brunner T, Green DR, Lin T. Fas and Fas ligand in the gut and liver. Am J Physiol 2000; 278:354-366
96. Rust C, Gores GJ. Apoptosis and liver disease. Am J Med 2000; 108:567-574
97. Shimoda S, Nakamura M, Ishibashi H, et al. HLA DRB4.*010- restricted immunodominant T cell autoepitope of pyruvate dehydrogenase complex in primary biliary cirrhosis: Evidence of molecular mimicry in human autoimmune diseases. J Exp Med 1995; 181: 1835-1845
98. Agarwal K, Czaja AJ, Donaldson PT. A functional fas promoter polymorphism is associated with a severe phenotype in type I auto immune hepatitis characterised by early development of cirrhosis. Tissue Antigens 2007; in press.
99. Johnson GCL, Esposito L, Barratt BJ, et al. Haplotype tagging for the identification of common disease genes. Nat Genet 2001; 29: 233-237
100. Perrow KA. Genetic polymorphism of the immunoregulatory system with specific reference to apoptosis. Thesis submitted for the Degree of Doctor of Philosophy, University of Newcastle, 2005
101. Xang X, Cullen SN, Li JH, Chapman RW, Jewell DP. Susceptibility to primary sclerosing cholangitis is associated with polymorphisms of the intercellular adhesion molecule-1. J Hepatol 2004; 40: 375-379
102. Vogel A, Strasburg CP, Manns MP. Genetic association of vitamin D receptor polymorphism with primary biliary cirrhosis and autoimmune hepatitis. Hepatology 2002; 35:126-131
103. Corpechot C, Benlian B, Barbu V, Chazouilliers O, Poupon RE, Poupon R. Apolipoprotein E polymorphism, a marker of disease severity in primary biliary cirrhosis. J Hepatol 2001; 35:324-328
104. Collins FS, Green ED, Guttmacher AE, Guyer MS. A vision of the future of genomics research. Nature 2003; 422:635-847